Elekta Holds Full-Year Guidance as Sales Slip 2%

Elekta AB (EKTAF) reported first-quarter fiscal 2027 results showing a 2% decline in sales and weakness in China, but posted improved gross margins and reaffirmed its FY 2026-27 guidance.

Elekta AB (ticker: EKTAF), the Swedish maker of radiotherapy and radiosurgery systems used to treat cancer, opened its 2027 fiscal year with the kind of quarter that splits opinion: the top line went backwards, the margin line went forwards, and management refused to move its full-year targets.

Sales fell 2% in the first quarter. Gross margin improved. Guidance for fiscal 2026-27 was reaffirmed. And China, one of the largest single growth markets for capital medical equipment over the past decade, remained a drag. Those four facts, laid out on the company's earnings call and summarised by GuruFocus, describe a business trading volume for quality of revenue while it waits for one region to come back.

A margin story wrapped around a soft top line

For a capital equipment company, a 2% sales decline in a single quarter is not by itself alarming. Linear accelerators and treatment-planning systems are lumpy items: a hospital's order can slide a quarter on financing, construction schedules, or a tender process, and the revenue recognition slides with it. What matters more over a full cycle is whether the company is holding price and improving what it keeps from each unit sold.

On that measure, the quarter reads better than the headline. Improved gross margins in a period of falling sales means the improvement is not coming from operating leverage volume was down, after all. It has to be coming from mix, from pricing, from lower input or logistics costs, or from the growing weight of service and software revenue in the total. Service contracts on an installed base of treatment machines are recurring, high-margin, and largely insulated from the timing of new orders. As an installed base ages and expands, that revenue stream becomes a floor beneath the equipment cycle.

That is the structural argument for looking past a 2% dip. The counter-argument is equally simple: margin gains without volume gains eventually run out of road, because there is a limit to how much mix and cost discipline can offset a shrinking base of new installations.

Why China matters more than its share of revenue

China has been the swing factor for Western medical device makers for several years, and Elekta named it directly as a source of weakness. The pressures there are well documented across the sector: government-led volume-based procurement that compresses prices, an anti-corruption drive that slowed hospital purchasing decisions, tighter local government budgets, and a domestic manufacturing push that favours homegrown suppliers in public tenders.

None of those are quarterly problems. They are structural changes to how a large market buys equipment, and they alter the arithmetic for any foreign vendor that built its growth model on Chinese hospital expansion. For Elekta, the practical question is not whether China recovers to its old trajectory but whether the rest of the portfolio Europe, North America, and the emerging markets outside China where radiotherapy access is still severely under-built can carry the growth line on its own.

Radiotherapy capacity per capita in much of Africa, South Asia and Latin America remains a fraction of the level in developed markets. That is the long-run demand argument the company and its peers lean on. It is real, but it converts into revenue slowly, and typically at lower price points and with more financing complexity than a Chinese or European tender.

What reaffirming guidance actually commits management to

Reaffirming FY 2026-27 guidance after a quarter with declining sales is a deliberate signal. It tells investors that management believes the shortfall is timing rather than demand destruction that orders exist, that they will convert, and that the back half of the fiscal year carries the weight.

It also raises the stakes. A company that holds guidance through a weak first quarter has spent some of its credibility buffer. If the second quarter also comes in soft, the reaffirmation becomes the story, and the eventual revision hits harder than an early trim would have. Investors watching this name through the rest of the fiscal year should treat the following as the checkpoints:

• Order intake, not just sales. Bookings lead revenue by several quarters in this business. Growing orders alongside falling sales is a timing problem; falling orders alongside falling sales is a demand problem.
• The direction of gross margin. One quarter of expansion is a data point. Two or three make it a trend and validate the mix and pricing thesis.
• Whether China stabilises or deteriorates further. Stabilisation at a lower level is manageable and can be planned around. Continued erosion is not.
• Service and software as a share of the total. The higher that share, the less any single equipment quarter matters.

How the shares sit going into the rest of the year

Elekta's shares under the EKTAF quotation last changed hands at 5.65, up 0.89% from a prior close of 5.60, with the day's range pinned at 5.65 on both ends as of the last trade on 4 September 2026. That single-print range is characteristic of a thinly traded secondary quotation rather than a liquid primary listing, and it is worth remembering that price discovery for this company happens on its home market, not on the line most American screens display.

The broader tape that day was mixed. The S&P 500, tracked by SPY, closed at $770.19, down 0.39%. The Dow 30 proxy DIA closed at $534.08, off 0.53%. The Nasdaq 100 proxy QQQ was the outlier on the upside at $718.96, up 0.18%. In other words, a modestly negative session for the broad market with technology holding up not a backdrop that explains much about a single European medtech quote either way.

The wider read across medical capital equipment

Elekta's quarter fits a pattern visible across the hospital capital equipment complex. Demand for cancer treatment is not cyclical patient volumes do not fall in a slowdown but hospital capital budgets very much are. Reimbursement pressure, higher borrowing costs for hospital construction, and staffing shortages that limit how many new treatment rooms a facility can actually operate all sit between underlying clinical need and a signed purchase order.

That gap is why margin discipline has become the industry's preferred lever. If you cannot reliably grow units in a given year, you protect price, push service attachment, and lean on software upgrades to the machines already installed. Elekta's first quarter is a clean example of that playbook in operation: sales down, margin up, guidance intact.

The verdict rests on the next two prints. If order intake confirms that the sales dip was schedule-driven and China merely stops getting worse, the reaffirmed guidance holds and the margin trend becomes the story of the year. If neither happens, the company will have to choose between its guidance and its credibility and in capital equipment, that choice usually only gets made once.

Frequently asked questions

What did Elekta report for its fiscal first quarter of 2027?

Elekta reported a 2% decline in sales for the quarter, alongside improved gross margins. Management reaffirmed guidance for fiscal year 2026-27. The company also flagged continued weakness in China, which has been a difficult market for foreign medical capital equipment vendors amid procurement reform and slower hospital purchasing.

Why did gross margins improve if sales declined?

When sales fall but gross margin rises, the gain cannot come from volume leverage. It typically reflects a better product mix, firmer pricing, lower input or freight costs, or a rising share of high-margin service and software revenue from the installed base of treatment machines already in hospitals.

What is happening in Elekta's China business?

Elekta cited China as a source of weakness. Across the medical device sector, China has been pressured by volume-based government procurement that compresses prices, an anti-corruption campaign that slowed hospital buying, constrained local budgets, and policy support for domestic manufacturers in public tenders. These are structural, not one-quarter, headwinds.

What does reaffirming guidance signal to investors?

Holding full-year guidance after a quarter of falling sales signals that management views the shortfall as a timing issue rather than lost demand, and expects orders to convert later in the fiscal year. It also concentrates the risk: if the second quarter is soft too, any eventual revision lands harder.

Where do EKTAF shares trade and what was the last price?

EKTAF last changed hands at 5.65, up 0.89% from a prior close of 5.60, as of the last trade on 4 September 2026. The day's range was a single print at 5.65, typical of a thinly traded secondary quotation. Primary price discovery for Elekta occurs on its home market in Sweden.

What should investors watch in Elekta's next results?

Four things: order intake, which leads revenue by several quarters in capital equipment; whether gross margin expansion repeats and becomes a trend; whether China stabilises at a lower level or keeps eroding; and the growing share of recurring service and software revenue, which cushions lumpy equipment sales.

Sources

• Elekta AB (EKTAF) (Q1 2027) Earnings Call Highlights: Margin Expansion and Strategic Resilience ... — GuruFocus

Photo: Andre · Pexels Licence — source